The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Developing a mouse model to elucidate the molecular mechanisms of Richter’s transformation
There are limited models to understand the progression of chronic lymphocytic leukemia (CLL) to Richter’s transformation (RT). In this interview, Prajish Iyer, PhD, City of Hope, Duarte, CA, discusses a B-cell-restricted mouse model developed by his team to allow for the study of this transition and the elucidation of the molecular mechanisms responsible for the occurrence of RT. MGA (Max gene associated), a functional MYC suppressor, was knocked out in this murine model, leading to mitochondrial dysfunction and elevated oxidative phosphorylation (OXPHOS). Nme1 (nucleoside diphosphate kinase) was identified as an MGA target, and Dr Iyer highlights that targeting the MGA-Nme1 axis may present a new therapeutic strategy for patients with RT. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
